跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
记能达 - NMPA Drug Approval Details
Approvals
/
NMPA
/
Donanemab Injection
Approved
生物制品
Donanemab Injection
Eli Lilly and Company
🇨🇳 National Medical Products Administration
Approval Date
Dec 17, 2024
Approval ID
8fjS3QliqTG
Company
Eli Lilly and Company
Type
生物制品
Approval Details
Approval Id
8fjS3QliqTG
Approval Number
国药准字SJ20240047
Generic Name
多奈单抗注射液
Generic Name En
Donanemab Injection
Trade Name
记能达
Drug Type
生物制品
Dosage Form
注射剂
Strength
20ml:350mg
Reg Date
2024-12-17
Expired Date
2029-12-16
Company Name
Eli Lilly and Company
Production Company Name
LILLY FRANCE
Company Detail Path
/organization/eli-lilly-cdr-cad-hedged
Production Company Detail Path
/organization/lilly-france
Approved
Quick Info
Agency
NMPA
Country
🇨🇳
Approval Date
Dec 17, 2024
Approval ID
8fjS3QliqTG
Type
生物制品
Back to NMPA Approvals